+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID06782542

Phase 2 Study of Oral Olutasidenib, Venetoclax, and Azacitidine Treatment in Adults with Newly Diagnosed IDH1 Mutated Acute Myeloid Leukemia Eligible for Intensive Chemotherapy

Led by Justin Watts, MD · Updated on 2026-04-16

16

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination treatment of olutasidenib, venetoclax, and azacitidine for adults aged 18 to 75 with newly diagnosed acute myeloid leukemia AML that has an IDH1 mutation. This Phase 2 study aims to compare the side effects and effectiveness of this combination treatment against the usual chemotherapy given to patients eligible for intensive induction chemotherapy. Participants will receive the combination treatment orally and by injection for up to 12 cycles, each lasting 28 days, totaling about 14 months of participation. Olutasidenib is given twice daily on an empty stomach continuously, venetoclax is self-administered once daily with a meal following a ramp-up dosing schedule in the first cycle, and azacitidine is administered by injection or infusion on days 1 through 7 of each cycle. During the study, participants will be monitored for side effects and treatment responses including remission rates and survival outcomes. Researchers will also assess pharmacokinetics and track adverse events for up to 13 months, with some outcomes followed for up to 36 months. Participants must attend regular visits for evaluations and tests, and agree to contraception and other study requirements throughout the trial period.

CONDITIONS

Brief Title

Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

Research Team

J

Justin Watts, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here